Abstract
Acute myeloid leukaemia (AML) is the most common form of leukaemia in adults. Although of the order of 75-85% of patients will achieve complete remission after induction chemotherapy, long-term survival is still relatively low. Despite the progress in the rational design of drugs in disorders such as chronic myeloid leukaemia, AML lacks a single specific pathogenomic event to act as a drug target. Interferon regulatory factor 1 (IRF1) is a member of a family of related proteins that act as transcriptional activators or repressors. IRF1 and its functional antagonist IRF2 originally discovered as transcription factors regulating the interferon-β (IFN-β) gene, are involved in the regulation of normal haematopoiesis and leukaemogenesis. IRF1 appears to act as a tumour suppressor gene and IRF2 as an oncogene. IRF1 acts to repress IRF2 function through the repression of cyclin-dependent kinase (CDK) inhibitor p21WAF1 critical for cell growth control. It appears that the tumour suppression function of IRF1 is abolished by IRF2. This review focuses on the interaction between IRF1 and IRF2 in myeloid development and leukaemogenesis, particularly in relation to the Ras signalling pathway. IRF2 may be a viable and specific therapeutic target in human leukaemia.
Keywords: IRF1, IRF2, leukaemogenesis
Current Gene Therapy
Title: The Role of IRF1 and IRF2 Transcription Factors in Leukaemogenesis
Volume: 6 Issue: 5
Author(s): Ailyn Choo, Patricia Palladinetti, Toby Passioura, Sylvie Shen, Richard Lock, Geoff Symonds and Alla Dolnikov
Affiliation:
Keywords: IRF1, IRF2, leukaemogenesis
Abstract: Acute myeloid leukaemia (AML) is the most common form of leukaemia in adults. Although of the order of 75-85% of patients will achieve complete remission after induction chemotherapy, long-term survival is still relatively low. Despite the progress in the rational design of drugs in disorders such as chronic myeloid leukaemia, AML lacks a single specific pathogenomic event to act as a drug target. Interferon regulatory factor 1 (IRF1) is a member of a family of related proteins that act as transcriptional activators or repressors. IRF1 and its functional antagonist IRF2 originally discovered as transcription factors regulating the interferon-β (IFN-β) gene, are involved in the regulation of normal haematopoiesis and leukaemogenesis. IRF1 appears to act as a tumour suppressor gene and IRF2 as an oncogene. IRF1 acts to repress IRF2 function through the repression of cyclin-dependent kinase (CDK) inhibitor p21WAF1 critical for cell growth control. It appears that the tumour suppression function of IRF1 is abolished by IRF2. This review focuses on the interaction between IRF1 and IRF2 in myeloid development and leukaemogenesis, particularly in relation to the Ras signalling pathway. IRF2 may be a viable and specific therapeutic target in human leukaemia.
Export Options
About this article
Cite this article as:
Choo Ailyn, Palladinetti Patricia, Passioura Toby, Shen Sylvie, Lock Richard, Symonds Geoff and Dolnikov Alla, The Role of IRF1 and IRF2 Transcription Factors in Leukaemogenesis, Current Gene Therapy 2006; 6 (5) . https://dx.doi.org/10.2174/156652306778520683
DOI https://dx.doi.org/10.2174/156652306778520683 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies to Optimize the Effectiveness of Antifungal Treatment for Invasive Aspergillosis
Anti-Infective Agents Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
Current Medicinal Chemistry Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology Ponatinib: A Review of Efficacy and Safety
Current Cancer Drug Targets Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design In Silico Analysis of Amino Acid Sequences in Relation to Specificity and Physiochemical Properties of Mesophilic and Thermophilic Antileukemic L-Asparaginases
Current Biotechnology Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
Current Stem Cell Research & Therapy Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry